Ute Bartels1, Johannes Wolff1, Lia Gore1, Ira Dunkel1, Stephen Gilheeney1, Jeffrey Allen1, Stewart Goldman1, Michal Yalon1, Roger J Packer1, David N Korones1, Amy Smith1, Kenneth Cohen1, John Kuttesch1, Douglas Strother1, Sylvain Baruchel1, Janet Gammon1, Mark Kowalski1, Eric Bouffet1. 1. The Hospital for Sick Children, Toronto, Ontario, Canada (U.B., S.B., J.G., E.B.); The MD Anderson Cancer Center, Houston, Texas (J.W.); Children's Hospital Colorado, Anschutz Medical Campus, Aurora, Colorado (L.G.); Memorial Sloan Kettering Cancer Center, New York, New York (I.D., S.G.); NYU Langone Medical Center, New York, New York (J.A.); Ann & Robert H. Lurie Children's Hospital of Chicago Northwestern University Feinberg School of Medicine, Chicago, Illinois (S.G.); Sheba Medical Center, Tel Hashomer, Israel (M.Y.); Children's National Medical Center, Washington, DC (R.J.P.); University of Rochester Medical Center, Rochester, New York (D.N.K.); University of Florida, Gainesville, Florida (A.S.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland (K.C.); Vanderbilt Children Hospital, Nashville, Tenneessee (J.K.); Alberta Children's Hospital, Calgary, Alberta, Canada (D.S.); YM Biosciences Inc, Mississauga, Ontario, Canada (M.K.).
Abstract
BACKGROUND: The prognosis of diffuse intrinsic pontine glioma (DIPG) remains poor, with no drug proven to be effective. METHODS: Patients with clinically and radiologically confirmed, centrally reviewed DIPG, who had failed standard first-line therapy were eligible for this multicenter phase II trial. The anti-epidermal growth factor receptor (EGFR) antibody, nimotuzumab (150 mg/m(2)), was administered intravenously once weekly from weeks 1 to 7 and once every 2 weeks from weeks 8 to 18. Response evaluation was based on clinical and MRI assessments. Patients with partial response (PR) or stable disease (SD) were allowed to continue nimotuzumab. RESULTS: Forty-four patients received at least one dose of nimotuzumab (male/female, 20/24; median age, 6.0 years; range, 3.0-17.0 years). All had received prior radiotherapy. Treatment was well tolerated. Eighteen children experienced serious adverse events (SAEs). The majority of SAEs were associated with disease progression. Nineteen patients completed 8 weeks (W8) of treatment: There were 2 PRs, 6 SDs, and 11 progressions. Five patients completed 18 weeks (W18) of treatment: 1 of 2 patients with PR at W8 remained in PR at W18, and 3 of 6 children with SD at W8 maintained SD at W18. Time to progression following initiation of nimotuzumab for the 4 patients with SD or better at W18 was 119, 157, 182 and 335 days, respectively. Median survival time was 3.2 months. Two patients lived 663 and 481 days from the start of nimotuzumab. CONCLUSIONS: Modest activity of nimotuzumab in DIPG, which has been shown previously, was confirmed: A small subset of DIPG patients appeared to benefit from anti-EGFR antibody treatment.
BACKGROUND: The prognosis of diffuse intrinsic pontine glioma (DIPG) remains poor, with no drug proven to be effective. METHODS:Patients with clinically and radiologically confirmed, centrally reviewed DIPG, who had failed standard first-line therapy were eligible for this multicenter phase II trial. The anti-epidermal growth factor receptor (EGFR) antibody, nimotuzumab (150 mg/m(2)), was administered intravenously once weekly from weeks 1 to 7 and once every 2 weeks from weeks 8 to 18. Response evaluation was based on clinical and MRI assessments. Patients with partial response (PR) or stable disease (SD) were allowed to continue nimotuzumab. RESULTS: Forty-four patients received at least one dose of nimotuzumab (male/female, 20/24; median age, 6.0 years; range, 3.0-17.0 years). All had received prior radiotherapy. Treatment was well tolerated. Eighteen children experienced serious adverse events (SAEs). The majority of SAEs were associated with disease progression. Nineteen patients completed 8 weeks (W8) of treatment: There were 2 PRs, 6 SDs, and 11 progressions. Five patients completed 18 weeks (W18) of treatment: 1 of 2 patients with PR at W8 remained in PR at W18, and 3 of 6 children with SD at W8 maintained SD at W18. Time to progression following initiation of nimotuzumab for the 4 patients with SD or better at W18 was 119, 157, 182 and 335 days, respectively. Median survival time was 3.2 months. Two patients lived 663 and 481 days from the start of nimotuzumab. CONCLUSIONS: Modest activity of nimotuzumab in DIPG, which has been shown previously, was confirmed: A small subset of DIPGpatients appeared to benefit from anti-EGFR antibody treatment.
Authors: L S Lashford; P Thiesse; A Jouvet; T Jaspan; D Couanet; P D Griffiths; F Doz; J Ironside; K Robson; R Hobson; M Dugan; A D J Pearson; G Vassal; D Frappaz Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: Ingo K Mellinghoff; Maria Y Wang; Igor Vivanco; Daphne A Haas-Kogan; Shaojun Zhu; Ederlyn Q Dia; Kan V Lu; Koji Yoshimoto; Julie H Y Huang; Dennis J Chute; Bridget L Riggs; Steve Horvath; Linda M Liau; Webster K Cavenee; P Nagesh Rao; Rameen Beroukhim; Timothy C Peck; Jeffrey C Lee; William R Sellers; David Stokoe; Michael Prados; Timothy F Cloughesy; Charles L Sawyers; Paul S Mischel Journal: N Engl J Med Date: 2005-11-10 Impact factor: 91.245
Authors: R J Packer; J M Boyett; R A Zimmerman; A L Albright; A M Kaplan; L B Rorke; M T Selch; J M Cherlow; J L Finlay; W M Wara Journal: Cancer Date: 1994-09-15 Impact factor: 6.860
Authors: R D Jenkin; C Boesel; I Ertel; A Evans; R Hittle; J Ortega; R Sposto; W Wara; C Wilson; J Anderson Journal: J Neurosurg Date: 1987-02 Impact factor: 5.115
Authors: Alberto Broniscer; Fred H Laningham; Mehmet Kocak; Matthew J Krasin; Maryam Fouladi; Thomas E Merchant; Larry E Kun; James M Boyett; Amar Gajjar Journal: Cancer Date: 2006-03-15 Impact factor: 6.860
Authors: Alberto Broniscer; Sharyn D Baker; Cynthia Wetmore; Atmaram S Pai Panandiker; Jie Huang; Andrew M Davidoff; Arzu Onar-Thomas; John C Panetta; Thomas K Chin; Thomas E Merchant; Justin N Baker; Sue C Kaste; Amar Gajjar; Clinton F Stewart Journal: Clin Cancer Res Date: 2013-03-27 Impact factor: 12.531
Authors: Z Gokce-Samar; P A Beuriat; C Faure-Conter; C Carrie; S Chabaud; L Claude; F Di Rocco; C Mottolese; A Szathmari; C Chabert; D Frappaz Journal: Childs Nerv Syst Date: 2016-07-05 Impact factor: 1.475
Authors: Lindsey M Hoffman; Sophie E M Veldhuijzen van Zanten; Niclas Colditz; Joshua Baugh; Brooklyn Chaney; Marion Hoffmann; Adam Lane; Christine Fuller; Lili Miles; Cynthia Hawkins; Ute Bartels; Eric Bouffet; Stewart Goldman; Sarah Leary; Nicholas K Foreman; Roger Packer; Katherine E Warren; Alberto Broniscer; Mark W Kieran; Jane Minturn; Melanie Comito; Emmett Broxson; Chie-Schin Shih; Soumen Khatua; Murali Chintagumpala; Anne Sophie Carret; Nancy Yanez Escorza; Timothy Hassall; David S Ziegler; Nicholas Gottardo; Hetal Dholaria; Renee Doughman; Martin Benesch; Rachid Drissi; Javad Nazarian; Nada Jabado; Nathalie Boddaert; Pascale Varlet; Géraldine Giraud; David Castel; Stephanie Puget; Chris Jones; Esther Hulleman; Piergiorgio Modena; Marzia Giagnacovo; Manila Antonelli; Torsten Pietsch; Gerrit H Gielen; David T W Jones; Dominik Sturm; Stefan M Pfister; Nicolas U Gerber; Michael A Grotzer; Elke Pfaff; André O von Bueren; Darren Hargrave; Guirish A Solanki; Filip Jadrijevic Cvrlje; Gertjan J L Kaspers; William P Vandertop; Jacques Grill; Simon Bailey; Veronica Biassoni; Maura Massimino; Raphaël Calmon; Esther Sanchez; Brigitte Bison; Monika Warmuth-Metz; James Leach; Blaise Jones; Dannis G van Vuurden; Christof M Kramm; Maryam Fouladi Journal: J Clin Oncol Date: 2018-05-10 Impact factor: 44.544